APLS
Apellis Pharmaceuticals, Inc. NASDAQ Listed Nov 9, 2017$40.99
Mkt Cap $5.2B
52w Low $16.10
99.4% of range
52w High $41.14
50d MA $30.35
200d MA $25.32
P/E (TTM)
227.6x
EV/EBITDA
45.5x
P/B
13.9x
Debt/Equity
1.3x
ROE
6.0%
P/FCF
70.3x
RSI (14)
—
ATR (14)
—
Beta
-0.20
50d MA
$30.35
200d MA
$25.32
Avg Volume
5.2M
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
100 Fifth Avenue · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 41.12 | -0.3% | -0.3% | — | — | — | — | — |
| Feb 24, 2026 | AMC | -0.39 | -0.47 | -20.5% | 22.13 | +1.2% | -3.2% | +1.0% | -3.1% | -1.2% | -2.6% | — |
| Oct 30, 2025 | AMC | 1.03 | 1.67 | +62.1% | 20.73 | +1.3% | +3.6% | -3.6% | -1.1% | -2.5% | -1.2% | — |
| Jul 31, 2025 | AMC | -0.44 | -0.33 | +25.0% | 22.34 | -0.4% | +2.7% | +5.7% | -0.2% | -1.9% | +2.5% | — |
| May 7, 2025 | AMC | -0.36 | -0.74 | -105.6% | 17.99 | -1.0% | -1.0% | -2.9% | +1.3% | -1.4% | -3.4% | — |
| Feb 28, 2025 | AMC | -0.37 | -0.29 | +21.6% | 25.15 | -1.4% | -4.3% | +4.1% | +3.8% | -2.6% | -1.1% | — |
| Nov 5, 2024 | AMC | -0.32 | -0.46 | -43.8% | 28.08 | +6.6% | +2.7% | -0.3% | +4.3% | -1.3% | -1.1% | — |
| Aug 1, 2024 | AMC | -0.33 | -0.28 | +15.2% | 36.00 | -0.6% | +1.6% | -7.3% | +3.6% | -4.3% | +12.1% | — |
| May 7, 2024 | AMC | -0.54 | -0.54 | +0.0% | 43.90 | +0.5% | -3.6% | +0.5% | -1.2% | +2.4% | -4.2% | — |
| Feb 27, 2024 | AMC | -0.66 | -0.73 | -10.6% | 69.35 | +1.6% | -7.6% | -3.2% | +3.1% | +1.2% | -3.3% | — |
| Nov 1, 2023 | AMC | -0.84 | -1.17 | -39.3% | 49.90 | +1.4% | -1.2% | -5.0% | -2.9% | +4.1% | -0.7% | — |
| Jul 31, 2023 | AMC | -1.35 | -1.02 | +24.4% | 25.75 | -1.5% | -5.9% | -1.1% | -0.4% | +2.8% | -3.6% | — |
| May 4, 2023 | AMC | -1.42 | -1.56 | -9.9% | 84.37 | +9.6% | +10.4% | -1.9% | -2.1% | +2.1% | -3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 24 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $32.72 | $32.77 | +0.2% | -6.0% | -0.5% | -2.4% | -1.3% | -2.1% |
| Sep 23 | Baird | Maintains | Outperform → Outperform | — | $32.51 | $32.23 | -0.9% | +0.6% | -6.0% | -0.5% | -2.4% | -1.3% |
| Sep 20 | Needham | Maintains | Buy → Buy | — | $36.73 | $34.00 | -7.4% | -11.5% | +0.6% | -6.0% | -0.5% | -2.4% |
| Sep 20 | Mizuho | Maintains | Neutral → Neutral | — | $36.73 | $34.00 | -7.4% | -11.5% | +0.6% | -6.0% | -0.5% | -2.4% |
| Sep 13 | JP Morgan | Maintains | Overweight → Overweight | — | $36.78 | $36.29 | -1.3% | +2.3% | -3.5% | -2.1% | +0.3% | +3.1% |
| Aug 13 | JP Morgan | Maintains | Overweight → Overweight | — | $36.16 | $36.30 | +0.4% | -1.2% | +0.8% | +4.4% | -1.0% | +3.5% |
| Aug 9 | UBS | Maintains | Buy → Buy | — | $37.66 | $37.68 | +0.1% | -1.7% | -2.3% | -1.2% | +0.8% | +4.4% |
| Aug 9 | Baird | Maintains | Outperform → Outperform | — | $37.66 | $37.68 | +0.1% | -1.7% | -2.3% | -1.2% | +0.8% | +4.4% |
| Aug 9 | Wedbush | Maintains | Neutral → Neutral | — | $37.66 | $37.68 | +0.1% | -1.7% | -2.3% | -1.2% | +0.8% | +4.4% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $37.66 | $37.68 | +0.1% | -1.7% | -2.3% | -1.2% | +0.8% | +4.4% |
| Aug 9 | Goldman Sachs | Maintains | Buy → Buy | — | $37.66 | $37.68 | +0.1% | -1.7% | -2.3% | -1.2% | +0.8% | +4.4% |
| Aug 2 | Goldman Sachs | Maintains | Buy → Buy | — | $36.00 | $35.80 | -0.6% | +1.6% | -7.3% | +3.6% | -4.3% | +12.1% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.00 | $35.80 | -0.6% | +1.6% | -7.3% | +3.6% | -4.3% | +12.1% |
| Aug 2 | Needham | Maintains | Buy → Buy | — | $36.00 | $35.80 | -0.6% | +1.6% | -7.3% | +3.6% | -4.3% | +12.1% |
| Jul 31 | Jefferies | Maintains | Buy → Buy | — | $39.23 | $39.50 | +0.7% | +0.9% | -9.1% | +1.6% | -7.3% | +3.6% |
| Jul 26 | Baird | Maintains | Outperform → Outperform | — | $38.88 | $38.98 | +0.3% | +2.2% | -1.2% | -0.1% | +0.9% | -9.1% |
| Jul 23 | Baird | Maintains | Outperform → Outperform | — | $37.05 | $36.74 | -0.8% | -0.5% | +1.4% | +4.0% | +2.2% | -1.2% |
| Jul 17 | Goldman Sachs | Maintains | Buy → Buy | — | $41.15 | $40.32 | -2.0% | -4.0% | -3.9% | +0.1% | -2.4% | -0.5% |
| Jun 28 | Baird | Maintains | Outperform → Outperform | — | $41.52 | $39.52 | -4.8% | -7.6% | -5.4% | -3.6% | +1.2% | +2.3% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.61 | $41.14 | +1.3% | -0.1% | +1.4% | -0.9% | -3.7% | +2.2% |
| May 23 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $43.60 | $43.02 | -1.3% | -9.0% | +2.3% | -0.1% | +1.4% | -0.9% |
| May 8 | Citigroup | Maintains | Buy → Buy | — | $43.90 | $44.12 | +0.5% | -3.6% | +0.5% | -1.2% | +2.4% | -4.2% |
| May 8 | Needham | Maintains | Buy → Buy | — | $43.90 | $44.12 | +0.5% | -3.6% | +0.5% | -1.2% | +2.4% | -4.2% |
| May 8 | UBS | Maintains | Buy → Buy | — | $43.90 | $44.12 | +0.5% | -3.6% | +0.5% | -1.2% | +2.4% | -4.2% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.90 | $44.12 | +0.5% | -3.6% | +0.5% | -1.2% | +2.4% | -4.2% |
| Apr 29 | Mizuho | Maintains | Neutral → Neutral | — | $49.86 | $48.98 | -1.8% | -4.1% | -7.6% | +4.2% | +3.1% | -0.1% |
| Apr 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.93 | $50.00 | +4.3% | +4.0% | -4.1% | -7.6% | +4.2% | +3.1% |
| Apr 25 | Needham | Maintains | Buy → Buy | — | $49.93 | $49.27 | -1.3% | -4.0% | +4.0% | -4.1% | -7.6% | +4.2% |
| Apr 17 | Wedbush | Maintains | Neutral → Neutral | — | $51.82 | $51.67 | -0.3% | -7.3% | -1.1% | +0.0% | +0.2% | +2.3% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.79 | $51.76 | -0.1% | -0.6% | +0.6% | -7.3% | -1.1% | +0.0% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $53.81 | $53.77 | -0.1% | +2.4% | +3.1% | -2.0% | -7.1% | -0.6% |
| Mar 27 | Mizuho | Maintains | Neutral → Neutral | — | $59.00 | $59.36 | +0.6% | -0.9% | +0.5% | +1.6% | -6.7% | +2.2% |
| Mar 6 | JP Morgan | Maintains | Overweight → Overweight | — | $62.47 | $62.00 | -0.8% | -2.4% | +2.5% | -1.3% | -1.5% | -3.6% |
| Mar 4 | UBS | Maintains | Buy → Buy | — | $63.89 | $64.14 | +0.4% | +1.2% | -3.3% | -2.4% | +2.5% | -1.3% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.35 | $70.45 | +1.6% | -7.6% | -3.2% | +3.1% | +1.2% | -3.3% |
| Feb 28 | Wedbush | Maintains | Neutral → Neutral | — | $69.35 | $70.45 | +1.6% | -7.6% | -3.2% | +3.1% | +1.2% | -3.3% |
| Feb 16 | Mizuho | Maintains | Neutral → Neutral | — | $67.58 | $67.58 | +0.0% | +1.8% | -1.4% | -1.4% | +1.0% | +1.3% |
| Feb 6 | Baird | Maintains | Outperform → Outperform | — | $68.16 | $68.57 | +0.6% | -1.2% | -0.9% | +2.1% | +0.6% | -1.2% |
| Feb 5 | Jefferies | Upgrade | Hold → Buy | — | $62.56 | $65.74 | +5.1% | +9.0% | -1.2% | -0.9% | +2.1% | +0.6% |
| Jan 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $65.36 | $65.53 | +0.3% | +0.9% | -4.1% | -1.8% | +0.7% | +9.0% |
| Jan 24 | Needham | Maintains | Buy → Buy | — | $66.18 | $66.74 | +0.8% | +0.5% | -0.4% | -3.3% | +2.1% | +0.9% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $66.30 | $65.58 | -1.1% | -0.6% | -3.1% | -0.1% | +2.6% | +1.1% |
| Jan 17 | Baird | Maintains | Outperform → Outperform | — | $66.30 | $65.58 | -1.1% | -0.6% | -3.1% | -0.1% | +2.6% | +1.1% |
| Jan 12 | Wedbush | Maintains | Neutral → Neutral | — | $66.09 | $66.80 | +1.1% | +6.3% | -5.6% | -0.6% | -3.1% | -0.1% |
| Jan 11 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $69.36 | $69.42 | +0.1% | -4.7% | +6.3% | -5.6% | -0.6% | -3.1% |
| Jan 9 | Goldman Sachs | Maintains | Buy → Buy | — | $68.35 | $68.34 | -0.0% | +6.0% | -4.3% | -4.7% | +6.3% | -5.6% |
| Dec 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $52.18 | $52.21 | +0.1% | +1.0% | +6.3% | +3.6% | -5.2% | -0.9% |
| Dec 15 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $52.18 | $52.21 | +0.1% | +1.0% | +6.3% | +3.6% | -5.2% | -0.9% |
| Dec 15 | Citigroup | Maintains | Buy → Buy | — | $52.18 | $52.21 | +0.1% | +1.0% | +6.3% | +3.6% | -5.2% | -0.9% |
| Dec 14 | Needham | Maintains | Buy → Buy | — | $62.88 | $53.27 | -15.3% | -17.0% | +1.0% | +6.3% | +3.6% | -5.2% |
No insider trades available.
SC TO-T/A
! Medium
Apellis Pharmaceuticals, Inc. -- Tender Offer Amendment
Apellis Pharmaceuticals shareholders can tender shares at $41.00 per share in an ongoing acquisition, providing an exit opportunity at this specified price level.
May 6
8-K
Apellis Pharmaceuticals, Inc. -- 8-K Filing
Apellis Pharmaceuticals modified its executive separation plan to allow C-level officers, including named executives, to claim "Good Reason" severance if the company becomes a subsidiary, protecting them from losing termination benefits in an acquisition.
May 4
SC TO-T
!!! Very High
Unknown — Tender Offer
Apeilon Therapeutics shareholders have an opportunity to sell their shares at a predetermined price, suggesting potential acquisition or going-private transaction that could provide certainty versus biotech development risk.
Apr 14
8-K
Unknown — 8-K Filing
Biogen is acquiring Apellis for an upfront payment plus contingent value rights, signaling aggressive expansion into complement-driven therapies and providing Apellis shareholders a defined exit with potential earn-out upside.
Mar 31
8-K
Unknown — 8-K Filing
APLS shareholders face a 20-day tender offer deadline at a fixed price plus one contingent value right, suggesting acquisition interest that investors must evaluate against potential future upside or downside risks.
Mar 31
8-K
Apellis Pharmaceuticals, Inc. -- 8-K Filing
Apellis Pharmaceuticals' executive compensation includes change-of-control protections allowing Dolsten's RSUs and options to fully accelerate vesting upon company acquisition, incentivizing retention during potential M&A discussions.
Mar 2
Data updated apr 24, 2026 6:29pm
· Source: massive.com